Now part of the Sartorius Group
Sartorius, a global leader in the international pharmaceutical, bioanalysis solutions, and laboratory equipment provider, acquired these ground-breaking companies as a recent strategic expansion of the Sartorius portfolio to include highly innovative cell analysis platforms and products.
Novel analytical methods are crucial to enable scientific progress in the rapidly advancing areas of oncology, immuno-oncology, antibody discovery, neuroscience and stem cell research. Both the IncuCyte® and the IntelliCyt iQue® Screener PLUS systems provide specialized innovative instrumentation, software and reagents for live-cell analysis to accelerate discovery and development of new drugs and provide new insight into the mechanisms of disease at a speed, depth and scale not achievable with conventional cell analysis techniques.
“With Essen’s [IncuCyte®] real-time, live-cell analysis platform, we will add another key technology for advancing and accelerating drug discovery applications to our lab divisions’ portfolio...This powerful technology offers important synergies with our IntelliCyt business. Going forward, Sartorius is ready to provide our customers the broadest and, we believe, the most innovative portfolio for cell analysis in the industry.”
— Joachim Kreuzburg, CEO of Sartorius
The IncuCyte® S3 Live-Cell Analysis System is a real-time quantitative live-cell imaging and analysis platform that enables visualization and quantification of cell behavior over time by automatically gathering and analyzing images around the clock within a standard laboratory incubator. The system allows researchers to make time-lapsed, kinetic measurements from living cells over days and weeks thus providing insight into active biological processes in real time.
The iQue® Screener PLUS is a high throughput, suspension cell analysis platform that enables researchers to rapidly profile cell phenotype and function in biologics, small molecule, and cell therapy discovery workflows. Based on flow cytometry but built for screening, the system allows researchers to automatically acquire and analyze high content, multiplexed assays needed to assess immune cell function by combining cell immuno-phenotyping, cell health, and secreted protein (cytokine) analysis in every well of microtiter plates.
Key advantages over current methods include: